Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.160
-0.010 (-0.85%)
Dec 5, 2025, 4:00 PM EST - Market closed
Company Description
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.
It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories.
The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product.
Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V.
| Country | Germany |
| Founded | 2021 |
| IPO Date | Nov 5, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, 55129 Germany | |
| Phone | 49 6131 554 2860 |
| Website | mainzbiomed.com |
Stock Details
| Ticker Symbol | MYNZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001874252 |
| CUSIP Number | N5436L101 |
| ISIN Number | NL0015000LC2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guido Baechler | Chief Executive Officer and Executive Director |
| William J. Caragol CPA | Chief Financial Officer and Senior Vice President |
| Dr. Christopher Von Toerne P.M.P., Ph.D. | Chief Operating Officer |
| Stefan Erlach | Head of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | F-3 | Filing |
| Nov 26, 2025 | 424B5 | Filing |
| Nov 26, 2025 | 6-K | Report of foreign issuer |
| Oct 3, 2025 | 6-K | Report of foreign issuer |
| Oct 3, 2025 | 424B5 | Filing |
| Oct 3, 2025 | 424B3 | Prospectus |
| Sep 26, 2025 | 6-K | Report of foreign issuer |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Aug 5, 2025 | 424B3 | Prospectus |